Literature DB >> 6310043

Characterization of viral RNA in cells transformed by various isolates of Moloney murine sarcoma virus.

R Hamelin, J Devaux, N Honoré, M A Auger-Buendia, A Tavitian.   

Abstract

Intracellular polyadenylated viral RNA from cells infected by five different isolates of Moloney murine sarcoma virus (Mo-MuSV) was analysed by gel transfer hybridization. Genomic sizes of 4.6 kilobases (kb) for the ml-MuSV isolate, 5.2 kb for the m3- and 124-MuSV, 6.1 kb for the HTl-MuSV and 6.7 kb for the 78-Al-MuSV were determined. With the exception of the ml strain, subgenomic RNA species were found in cells infected by the various isolates. However, no common subgenomic RNA containing v-mos sequences could be characterized. Each transformed cell line expressed a different set of viral RNA species in terms of size and structure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6310043     DOI: 10.1099/0022-1317-64-9-2057

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  4 in total

1.  Reversion of thermosensitive splicing defect of Moloney murine sarcoma virus ts110 by oversplicing of viral RNA.

Authors:  R Hamelin; N Honore; D Sergiescu; B Singh; J Gerfaux; R B Arlinghaus
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

2.  Temperature-sensitive viral RNA expression in Moloney murine sarcoma virus ts110-infected cells.

Authors:  R Hamelin; B L Brizzard; M A Nash; E C Murphy; R B Arlinghaus
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

3.  Temperature-sensitive splicing defect of ts110 Moloney murine sarcoma virus is virus encoded.

Authors:  R Hamelin; K Kabat; D Blair; R B Arlinghaus
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

4.  Persistent expression of v-mos oncogene in transformed cells that revert to nonmalignancy after prolonged treatment with interferon.

Authors:  D Sergiescu; J Gerfaux; A M Joret; C Chany
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.